No Downstaging After Short-Term Preoperative Radiotherapy in Rectal Cancer Patients


Purpose: In retrospective studies, total mesorectal excision (TME) surgery has been demonstrated to result in a reduction in the number of local recurrences of rectal cancer. Reports on improved local control after preoperative, hypofractionated radiotherapy have led to the introduction of a randomized multicenter trial to evaluate the effect of TME surgery with and without preoperative radiotherapy. Treatment with preoperative radiotherapy might have an effect on the pathologic characteristics that determine staging of rectal cancer. We investigated the occurrence of downstaging in rectal cancer patients treated with and without preoperative radiotherapy.

Patients and Methods: We analyzed the differences in tumor size, number of examined lymph nodes, tumor-node-metastasis stage, and histopathologic features in 1,321 patients entered onto a randomized trial.

IN RECTAL CANCER, the most important predictive factor for survival or recurrence after potentially curative surgery is the tumor-node-metastasis stage of the disease. This is determined by the depth of penetration through the bowel wall and the presence and number of tumor-containing lymph nodes. Both of these criteria can only be determined postoperatively.

In attempt to reduce the high local recurrence rates in rectal cancer patients after curative surgery, the value of additional preoperative1-10 or postoperative11-15 radiotherapy (RT) has been investigated in a series of clinical trials. Treatment with preoperative RT might have an effect on the pathologic characteristics that determine staging in rectal cancer patients. If such an effect occurs, the staging of rectal cancer patients who undergo only potentially curative surgery will be systematically different from the staging of patients who receive preoperative RT followed by curative surgery. As a consequence, migration of patients from one stage to another might occur. This phenomenon, which sometimes is called Will Rogers phenomenon, is well documented in gastric cancer after D1 or D2 resection.16,17 The possible occurrence of downstaging is important to decisions for which staging is relevant, for the selection of patients for adjuvant therapy, and for comparison of different treatment strategies.

In a large Swedish rectal cancer trial, preoperative hypofractionated RT resulted in better local control than postoperative RT.1 The beneficial effect of preoperative RT demonstrated in the SRC trial was observed in combination with standard surgery.19 The acknowledgment of the important role of circumferential margin involvement in the local recurrence of rectal cancer18 has led to the introduction of total mesorectal excision (TME) surgery, as advocated by Heald19 and Enker.20

To analyze whether preoperative RT is beneficial in TME-treated patients, a randomized, international multicenter trial was conducted under the auspices of the Dutch
Colorectal Cancer Group to evaluate the effect of preoperative, hypofractionated RT and TME surgery versus TME surgery alone. The overall results are expected to be published in 2001. We have analyzed currently the occurrence of stage migration as a result of preoperative RT in patients entered onto this study.

The effect of RT on pathologic characteristics, and consequently on the occurrence of downstaging in rectal cancer, depends on total dose, fractionation size, and the interval between the start of RT and the day of surgery, which is called the overall treatment time (OTT). Trials on which patients have an OTT greater than 4 weeks generally demonstrate downstaging. Some trials have reported a decrease in the number of patients with involved lymph nodes after administration of $5 \times 5$ Gy. The present study was undertaken to assess the effect of short-term preoperative RT on tumor characteristics such as staging, grading, nodal spread, and size in resected rectal cancer specimens from a large multicenter trial with standardized RT, surgery, and pathology.

**PATIENTS AND METHODS**

**Study Population**

Primary rectal cancer patients who were included in a large multicenter trial in the Netherlands were studied. From January 1996 through December 1999, more than 1,500 patients were randomized to receive preoperative RT followed by standardized TME surgery or TME surgery alone.

Patients entered onto the study were required to have biopsy confirmation of rectal adenocarcinoma, resectable tumor as judged by clinical examination, tumor within 15 cm of the anal verge, no signs of distant metastases, and no hereditary polyposis. Patients in whom a malignancy was diagnosed previously, or who had received either chemotherapy or RT to the pelvis, were not included in the study. Furthermore, patients had to be considered fit for surgery as well as for RT. Informed consent was obtained from all patients.

Randomization to RT followed by TME surgery or TME surgery alone occurred only after stratification for surgical institute and expected type of resection. Central randomization was performed with balanced lists and a block size of six. A total of 1,530 patients were included on the trial, of which 117 turned out to be ineligible for reasons listed in Table 1. To evaluate the effect of short-term preoperative RT on pathologic tumor characteristics, patients also were excluded from analysis in the RT group because either the total dose received was less than 25 Gy (n = 14), or the time interval between the start of radiation and surgery was greater than 10 days (n = 78). Thus, 1,321 patients remained assessable.

**Preoperative RT**

The patients assigned to preoperative RT received a total dose of 25 Gy in five fractions for 5 to 7 days. The prescribed dose was specified according to the guidelines in the International Commission on Radiation Units Report 50. The clinical target volume included the primary tumor and the mesentery, with vascular supply that contained the perirectal, presacral, and internal iliac nodes (up to the S1-S2 junction). The upper border of the planning target volume was L5-S1 in 84% of patients and S1-S2 in 16% of patients. The perineum was included if an abdominoperineal resection was planned, whereas the lower border was 3 cm above the anal verge if the planned operation was a low anterior resection. The irradiation was administered with a four-portal field in 26% of patients and with a three-portal field in 74% of patients.

**Surgery**

According to the protocol, surgery was to be performed within 10 days after the first day of irradiation. All patients underwent surgery according to the TME principles. The main principles of this operative technique involve sharp dissection within the true pelvis around the integral mesentery under direct vision, envelopment of the entire midrectum, and preservation of the hypogastric plexus.

**Pathology Procedures**

Standardized routine pathology examinations were performed in the pathology laboratories of the referring hospitals as has been described by Quirke et al. Pathologic information for all patients’ resected tumors was recorded prospectively by pathologists from the referring hospital on a standard pathology case record form. A pathology quality manager and a pathology review committee were installed to ensure consistent quality of all pathology data and procedures.

Careful examination of the circumferential resection margin was performed, and tumor invasion of the bowel wall and surrounding tissue was investigated. The largest diameter of the tumor was registered after fixation of the specimen. The specimens were examined for lymph nodes, and all lymph nodes found were processed for microscopic investigation.

Tumor staging was performed by use of the tumor-node-metastasis classification, and the Jass classification was used by the pathology review committee. A summary of the Jass classification is provided in the Appendix. In addition, the pathology review committee classified the tumors according to their histologic differentiation as well differentiated, moderately differentiated, poorly differentiated, and undifferentiated adenocarcinoma. The World Health Organization criteria as
presented in 1976 by Morson and Sobin, with the modification of Blenkinsopp et al., were used. The grading decision was based on the least differentiated area. The tumor was considered mucinous if more than 50% of the adenocarcinoma was mucinous.

Data Collection and Statistics

All case record forms were sent to the central data office at the department of surgery in Leiden. After the data were checked, they were entered in a database and analyzed with the SPSS 9.0 software for Windows (SPSS, Inc, Chicago, IL).

Mann-Whitney U tests were used to compare quantitative and ordered variables, and Student’s t test was used to analyze differences in normally distributed data between the two groups. $\chi^2$ tests were used to compare proportions. A $P$ value $\leq 0.05$ was considered statistically significant.

Previous Randomized Trials

To compare the effect of preoperative RT on stage migration, all randomized trials with preoperative RT were analyzed. The difference in the percentage of patients with tumor-node-metastasis stage III disease in the nonirradiated group, minus the RT plus surgery group, was calculated and plotted graphically with 95% confidence intervals.

RESULTS

Patient Characteristics

Table 2 lists distributions of age, sex, tumor localization, operation type, and distant metastases for the two treatment arms. There were no significant differences in these factors among the individual treatment arms. For the patients treated with RT, the time from initiation of RT up to and including the day of surgery (the OTT) is listed in Table 2.

Pathologic Staging Characteristics

The mean tumor size (largest diameter) was significantly smaller in the irradiated group than in the surgery-only patient group (Table 3). The mean diameter of irradiated tumors was 4.0 cm compared with 4.5 cm for the nonirradiated tumors ($P < .001$). Nonetheless, there was no significant difference in tumor classification between the groups.

The total number of lymph nodes examined was significantly smaller in the irradiated group as compared with the nonirradiated group ($P < .001$). Overall, the mean value of examined lymph nodes was 9.7 in the control group and 7.7 in the irradiated group. There was no difference between the groups in the mean number of positive lymph nodes: 1.6 in the RT group and 1.9 in the control group. In addition, in stage III tumors only, no difference between the number of involved lymph nodes was observed. The distribution between both groups with regard to node classification was balanced: 39% nodal involvement in the combined treatment arm and 42% involvement in the surgery-only arm. The distribution of tumor-node-metastasis stages was similar between both treatment arms (Fig 1). The number of patients with tumor-node-metastasis stage III was 34% in the irradiated group and 38% in the nonirradiated group.

Histopathologic Characteristics

The differentiation grades demonstrated more poorly differentiated tumors in the irradiated group than in the non irradiated group (Table 3; $P < .001$). There were also
significantly more mucinous tumors in the first group ($P < .001$).

The proportion of peritumoral lymphocytic infiltration was scored on slides stained with hematoxylin and eosin. The irradiated tumors demonstrated extensive lymphoid reaction in 6.8% of the cases versus 17.9% in the nonirradiated tumors ($P < .001$). The type of invasion (circumscribed vs diffuse) did not vary between the groups. The distribution over the Jass classification demonstrated a lower Jass classification in the irradiated group (Fig 2).

Previous Randomized Trials

To compare the effect of different preoperative RT schemes on lymph node involvement, all randomized trials with preoperative RT for operable rectal cancer were analyzed. Table 4 summarizes these trials with dose, fractionation, and overall treatment time and the differences in tumor stage, size, number of lymph nodes examined, and histologic differentiation if published. The percentage of stage III tumors is expressed in comparison with stage I and II tumors unless otherwise stated. In general, the trials with a long OTT demonstrate more downstaging than trials with a short OTT. The SRC trial$^{22}$ is divided in two subgroups: patients with an OTT less than 10 days and patients with an OTT greater than 10 days. Tumor size was smaller in all irradiated groups than in the surgery-only groups.

To visualize the differences in the percentage of patients with tumor-node-metastasis stage III, the 95% confidence bars of the difference are plotted in Fig 3. The trials are grouped by the duration of the OTT.

DISCUSSION

These results demonstrate that after short-term preoperative RT, a decrease in the tumor size and the number of recovered lymph nodes is observed, but there is no change in the tumor classification and node classification. Therefore, downstaging has not occurred in our trial. We suggest that the disappearance of negative lymph nodes is caused by rapid apoptosis of lymphocytes in contrast to tumor cells.

Preoperative RT is administered for several indications. Apart from reduction in the number of local recurrences, downstaging is one of the main purposes of conventional schemes, which now are combined frequently with chemotherapy. Tumor reduction is useful to achieve resectability in locally advanced tumors or to allow sphincter-saving procedures in low tumors. It is unlikely that a greater number of sphincter-saving procedures can be performed after short-term RT, because downstaging is
not the mechanism by which the reduction in local recurrence is achieved.

According to the literature, several factors seem to play a role in the occurrence of downstaging after preoperative RT. One factor is the fraction size and total dose applied. This is directly correlated with the time interval between the first fraction of RT and the date of surgery (the so-called OTT). In studies in which doses of 40 Gy or more are given in a conventional fractionation scheme, this automatically leads to an OTT of more than 4 weeks, which provides time for the tumor to shrink. In short-term RT, however, the overall treatment time is usually 2 weeks at most. The relevance of the interval between RT and surgery in rectal cancer has been investigated recently by Francois et al. After a dose of 30 to 39 Gy, they found no difference in stage III tumors following an interval of 2 or 6 weeks between RT and surgery. This might be explained by the median interval between RT and surgery, which was already 13 days in the short interval (range, 1 to 63 days).

There have been several reports on downstaging in rectal cancer after randomized trials with preoperative RT. A summary of those studies is listed in Table 4 and Fig 3. Most studies with an interval that exceeds 4 weeks demonstrate fewer patients with Dukes’ C stage in the irradiated group. In the European Organization for Research and Treatment of Cancer trial, surgery was performed immediately after RT. No difference in Dukes’ C staging was observed. The reports on downstaging in the short-term RT group (<2 weeks) varied. No difference was seen (nor expected) in the Medical Research Council I trial in the group that received 1 × 5 Gy or in the Toronto trial. This can be attributed to the low total dose.

Of the other trials with a short OTT, most did not detect downstaging. The SRC trial demonstrates less nodal involvement if all patients are analyzed together. If the groups are corrected for overall treatment time, the downstaging disappears completely. The Stockholm II trial also demonstrates downstaging, but of the 557 patients analyzed, 316 were also included in the report by Graf et al.

In our study, the OTT was not more than 10 days. This interval is too short for the tumor cells to disappear, and it explains our finding that there was no downstaging. We found smaller tumors in the RT arm, which is in accordance with the trials mentioned previously. When tumor size was reported, tumors were smaller in the RT group. To explain the differences in tumor diameter, we investigated whether the amount of lymphoid infiltration was a contributor. This hypothesis was developed because the number of lymph nodes found in the specimens decreased significantly in the irradiated group, and we found less lymphoid infiltration in irradiated tumors. There was no correlation between tumor size and extension of infiltration.

The number of lymph nodes examined was significantly lower in the irradiated group, but no decrease in the number of positive lymph nodes was observed. This is explained by the fact that lymphocytes can undergo cell death within hours after RT without cell division, whereas tumor cells need more time to undergo cell death. In patients with long intervals between

Table 4. Randomized Trials on Downstaging After Preoperative Radiotherapy for Rectal Cancer

<table>
<thead>
<tr>
<th>Trial</th>
<th>No. of Patients</th>
<th>Fraction × Dose, Gy</th>
<th>OTT (weeks)</th>
<th>TNM III S (%)</th>
<th>Tumor Size S (%)</th>
<th>Lymph Nodes %</th>
<th>Histology %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bergen4</td>
<td>269</td>
<td>18 × 1.75</td>
<td>7</td>
<td>18</td>
<td>28</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>EORTC II5</td>
<td>341</td>
<td>15 × 2.3</td>
<td>4</td>
<td>34</td>
<td>34</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>VASOG II33</td>
<td>320</td>
<td>18 × 1.75</td>
<td>6</td>
<td>36</td>
<td>42</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>MRC II7</td>
<td>248</td>
<td>20 × 2</td>
<td>&gt;8</td>
<td>30</td>
<td>59</td>
<td>22</td>
<td>16</td>
</tr>
<tr>
<td>Toronto34</td>
<td>125</td>
<td>1 × 5</td>
<td>1 day</td>
<td>44</td>
<td>29</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>MRC I6</td>
<td>824</td>
<td>1 × 5</td>
<td>1</td>
<td>46</td>
<td>45</td>
<td>42</td>
<td>16</td>
</tr>
<tr>
<td>VASOG I35</td>
<td>613</td>
<td>10 × 2</td>
<td>&gt;2</td>
<td>24</td>
<td>38</td>
<td>42</td>
<td>16</td>
</tr>
<tr>
<td>MRC I6</td>
<td>824</td>
<td>10 × 2</td>
<td>3</td>
<td>36</td>
<td>45</td>
<td>54</td>
<td>15</td>
</tr>
<tr>
<td>RCG/ICRG3</td>
<td>468</td>
<td>3 × 5</td>
<td>1</td>
<td>43</td>
<td>44</td>
<td>54</td>
<td>15</td>
</tr>
<tr>
<td>NWRCG36</td>
<td>284</td>
<td>4 × 5</td>
<td>1-2</td>
<td>47§</td>
<td>39§</td>
<td>50</td>
<td>42</td>
</tr>
<tr>
<td>Stockholm I9</td>
<td>849</td>
<td>5 × 5</td>
<td>1-2</td>
<td>32</td>
<td>31</td>
<td>25</td>
<td>15</td>
</tr>
<tr>
<td>Stockholm II37</td>
<td>557</td>
<td>5 × 5</td>
<td>1-2</td>
<td>28</td>
<td>38</td>
<td>42</td>
<td>15</td>
</tr>
<tr>
<td>SRC25</td>
<td>1316</td>
<td>5 × 5</td>
<td>1-2</td>
<td>34</td>
<td>40</td>
<td>45</td>
<td>23</td>
</tr>
<tr>
<td>Current trial</td>
<td>1530</td>
<td>5 × 5</td>
<td>1-2</td>
<td>34</td>
<td>40</td>
<td>45</td>
<td>23</td>
</tr>
</tbody>
</table>

Abbreviations: TNM, tumo-node-metastasis stage; S, surgery; EORTC, European Organization for Research and Treatment of Cancer; VASOG, Veterans’ Administration Surgical Oncology Group; MRC, Medical Research Council; RCG/ICRG, Rectal Cancer Group/Imperial Cancer Research Fund; NWRCG, Northwest Region Rectal Cancer Group; SRC, Swedish Rectal Cancer.

*Size in cm (Bergen median, others mean) or percentage of patients with tumors < 5 cm.
†Number of lymph nodes or percentage of patients with > 7 lymph nodes (MRC II).
‡Percentage of poorly differentiated tumors.
§TNM stage III and IV.
RT and surgery, lymphocytes reappear and tumor cells die, and these events lead to downstaging.

The differences in histology have been observed previously. The Northwest Region Rectal Cancer Group trial and the Stockholm I trial both reported an increase in poorly differentiated tumors in the irradiated groups. This was not observed in the Bergen and Medical Research Council II trial, both of which had OTTs of more than 4 weeks; the disappearance of cells is a possible explanation. Because grading is scored on the basis of the worst area, the presence of less lymphocytes increases the chance of finding such an area.

Despite the differences found after irradiation, no difference was found in tumor-node-metastasis stage. However, the irradiated group demonstrated a higher Jass classification, which resulted from the disappearance of the lymphocytic infiltrate, one of the Jass classification parameters. Therefore, the Jass classification is of limited value in comparing patients who have been irradiated preoperatively with nonirradiated patients.

In January 2000, the Dutch Colorectal Cancer Group initiated a new multicenter trial with optional randomization for preoperative RT until the results of the TME trial are known. Patients with tumor-node-metastasis stage II or III are randomized postoperatively for adjuvant chemotherapy (fluorouracil and leucovorin). The absence of downstaging guarantees a balanced distribution of tumor-node-metastasis stages across the different randomization groups, which prevents stage migration that would influence the eventual outcome of this new trial.

In addition, we conclude that short-term, preoperative RT does not contribute to downstaging if the overall treatment time is less than 10 days. Results that indicate better survival or fewer recurrences after this type of RT must be attributed to the effect of the RT.

### Table 5. Jass Classification: Scoring Criteria

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasion through the bowel wall</td>
<td></td>
</tr>
<tr>
<td>Limited to bowel wall</td>
<td>0</td>
</tr>
<tr>
<td>Transmural</td>
<td>1</td>
</tr>
<tr>
<td>Margin of the tumor</td>
<td></td>
</tr>
<tr>
<td>Pushing</td>
<td>0</td>
</tr>
<tr>
<td>Infiltrating</td>
<td>1</td>
</tr>
<tr>
<td>Peritumoral lymphocytic infiltrate</td>
<td></td>
</tr>
<tr>
<td>Conspicuous</td>
<td>0</td>
</tr>
<tr>
<td>Scant/absent</td>
<td>1</td>
</tr>
<tr>
<td>Lymph node metastases</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
</tr>
<tr>
<td>1–4 positive</td>
<td>1</td>
</tr>
<tr>
<td>&gt; 4 positive</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Jass Groups</th>
<th>Total Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0–1</td>
</tr>
<tr>
<td>II</td>
<td>2</td>
</tr>
<tr>
<td>III</td>
<td>3</td>
</tr>
<tr>
<td>IV</td>
<td>4–5</td>
</tr>
</tbody>
</table>
**APPENDIX**


**Cooperative clinical investigators include the following:**

REFERENCES

1. Frykholm GJ, Glimelius B, Pahlman L: Preoperative or postoperative irradiation in adenocarcinoma of the rectum: Final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 36:564-572, 1993


32. Dutch Colorectal Cancer Group: Preoperative radiotherapy and/or adjuvant chemotherapy combined with TME-surgery in operable rectal cancer. CKVO 1999-03


